Susan Schept

Want to learn a new healthy recipe and spice up your meal rotation? Join us from 12-1 pm ET for a vegan cooking class where you will learn how to make a curry sweet potato stew. All proceeds benefit the Cystic Fibrosis Foundation: #IworkforCFF passion.cff.org/vegancookingcl…

@repdonbeyer, as a constituent and someone deeply concerned for people with #cysticfibrosis, I’m calling on Congress to prioritize CF-related research and drug development by protecting the NIH and FDA. #CFadvocacy

@markwarner, as a constituent and someone deeply concerned for people with #cysticfibrosis, I’m calling on Congress to prioritize CF-related research and drug development by protecting the NIH and FDA. #CFadvocacy

@sentimkaine, as a constituent and someone deeply concerned for people with #cysticfibrosis, I’m calling on Congress to prioritize CF-related research and drug development by protecting the NIH and FDA. #CFadvocacy

Alyftrek, a new, once-a-day CFTR modulator for people with cystic fibrosis has been approved by the @US_FDA.

@NBCOlympics pls stop announcing results before you show the event!! Why watch if you already know what happens??

It's #CysticFibrosis Awareness Month, which means our #CrossOutCF campaign is back! Join us for a month of amplifying #CF voices, exploring science, sharing CF facts, celebrating progress, and forging forward! #CFAwarenessMonth #DareToDream Read more >> bit.ly/3JwqiWZ

May is Cystic Fibrosis Awareness Month! Did you know? There are approximately 1,000 new cases of cystic fibrosis diagnosed each year. #CFAwarenessMonth

We have invested more than $6.6 million in additional funding in Sionna Therapeutics to continue research into the development of potential new modulator therapies for people with #cysticfibrosis with an F508del mutation.

Phase 3 trial results were positive for the new vanzacaftor triple-combination modulator for people with CF, showing improvements in sweat chloride, though no improvement in lung function compared to Trikafta.

We’re investing up to $3M in ViaNautis, which is developing a non-viral mechanism that may address challenges in delivering a genetic therapy to the body. Genetic therapies have the potential to benefit all people with CF, regardless of their mutations. on.cff.org/46bPKcX

We are investing up to $9M in additional funds in Arcturus Therapeutics to test an mRNA therapy that could treat the underlying cause of #cysticfibrosis in all people with CF. An early-stage clinical trial in people with CF is planned for Q4 2023. on.cff.org/3RGghfb

We are providing up to $3.9M to TB Alliance to conduct lab testing of a compound that could eventually be used to treat infections caused by nontuberculous mycobacteria in people with #cysticfibrosis. #CFResearch on.cff.org/3OeEyap

The @US_FDA has approved Kalydeco for infants with cystic fibrosis ages 1-4 months who have certain mutations. Research indicates that early intervention with modulators can help slow or even prevent the irreversible progression of this disease. on.cff.org/3HE9AnO

The @US_FDA approved Trikafta for children with CF ages 2-5 years with at least one copy of the F508del mutation or one copy of certain mutations. With this approval, more than 900 children will have access to a CFTR modulator for the first time. cff.org/news/2023-04/t…

Thanks to advances in research and care, the proportion of adults with cystic fibrosis — at 62% — has surpassed that of children. While we’re encouraged by these trends, there is more to be done to meet the changing needs of the CF community.

A lively and thought provoking conversation about antimicrobial resistance on the @CDCFound’s Contagious Conversations podcast between myself, @DrJudyMonroe and @ThatMould. Thank you for inviting me as guest to share about the importance of spreading awareness!

We are investing up to $3.5M in Gensaic Inc. to conduct preclinical research to develop a new approach to deliver a gene therapy to the lung cells of people with #cysticfibrosis. on.cff.org/3ZmCu36

We’re excited to announce that we expanded our lab’s footprint, creating space for startup companies and industry scientists to work and learn alongside lab staff. By sharing our expertise, we will help speed up the development of new treatments. on.cff.org/3Fu4adj